This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Egan, B. M. Articles by Julius, S. Search for Related Content PubMed PubMed Citation Articles by Egan, B. M. Articles by Julius, S. Social Bookmarking                   What's this?

Review: Prehypertension: should we be treating with pharmacologic therapy?

Medical University of South Carolina, 135 Rutledge Avenue, RT1104, Charleston, SC 29425, eganbm{at}musc.edu

Shawna D. Nesbitt

University of Texas Southwestern, Dallas, Texas

Stevo Julius

University of Michigan, Ann Arbor, Michigan

Prehypertension, defined by Seventh Joint National Committee (JNC 7) as a blood pressure (BP) 120—139/80—89 mm Hg, was controversial. Approximately 31—37% of US adults are prehypertensive, and 12—14% have BP of 130—139/85—89 mm Hg or `Stage 2' prehypertension, is associated with 3-fold greater likelihood of developing hypertension and roughly twice the cardiovascular events than BP <120/80 mm Hg. Lifestyle change is the only intervention recommended for most prehypertensives. When fully implemented, lifestyle changes lower BP and prevent cardiovascular events, but evidence for community-wide effectiveness is limited. The Trial of Preventing Hypertension (TROPHY) documented that angiotensin receptor blockade safely lowers BP and prevents and/or delays hypertension in Stage 2 prehypertensives. Prehypertensives with diabetes or nephropathy are at high risk and should receive antihypertensive treatment according to JNC 7. Epidemiological data suggest that the number needed to treat to prevent a cardiovascular event in these at-risk Stage 2 prehypertensives is similar to Stage 1 hypertensives when both groups have one or more concomitant risk factors. Clinical trials are urgently needed to address this question. In the absence of clinical trials data, we believe it is prudent for the concerned clinician to consider initiating antihypertensive pharmacotherapy in selected Stage 2 prehypertensive patients at significant absolute risk for progression to hypertension and cardiovascular events.

Key Words: prehypertension • hypertension • cardiovascular disease • lifestyle change • pharmacologic therapy

Therapeutic Advances in Cardiovascular Disease, Vol. 2, No. 4, 305-314 (2008)
DOI: 10.1177/1753944708094226


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?